Stocks
Global Blood Therapeutics, Inc.GBT
NASDAQHealthcareBiotechnology$68.49+0.01%
Price as of · delayed, not real-time
Focused on developing novel therapeutics for blood disorders, this biopharmaceutical company gained attention for its work on sickle cell disease treatments. Investors closely followed its pipeline due to the high unmet medical need in hematology, particularly after Pfizer acquired the company in 2022.
Market Cap: $052W Range: $21.65-$73.02
Congressional Interest in Global Blood Therapeutics, Inc. (GBT)
1 member of Congress has disclosed 2 trades in Global Blood Therapeutics, Inc. (GBT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading GBT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-06-24 | Donna Shalala | sell | $1K-$15K |
| 2019-06-04 | Donna Shalala | buy | $1K-$15K |